Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

References

• Roche Pharma AG. Summary of product characteristics. Mabthera 100 mg concentrate for solution for infusion; 2016. Available from: https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Accessed January, 2020.
   Google Scholar
• Boumans MJH, Tak PP. Rituximab Treatment in Rheumatoid Arthritis: How Does It Work? Arthritis Res Ther.2009;1:(134) . doi:10.1186/ar2852.
   Google Scholar
• Genentech, Inc. Rituxan (rituximab) prescribing information; 2010. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103705s5311lbl.pdf. Accessed August 27, 2020.
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues; 2014. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed January, 2020.
   Google Scholar
• Abraham I, Sun D, Bagalagel A, et al. Biosimilars in 3D: definition, development and differentiation. Bioengineered. 2013;4(4):203–206. doi:10.4161/bioe.25067
   PubMed Web of Science ®Google Scholar
• Yoo DH, Suh C-H, Shim SC, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):566–570. doi:10.1136/annrheumdis-2016-209540
   PubMed Web of Science ®Google Scholar
• Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7:4.
   Google Scholar
• Simoens S, Jacobs I, Popovian R, Isakov L, Shane LG. Assessing the value of biosimilars: a review of the role of budget impact analysis. Pharmacoeconomics. 2017;35(10):1047–1062. doi:10.1007/s40273-017-0529-x
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilar Initiative Gabi. Biosimilars approved in Europe; 2020. Available from: http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe. Accessed July 25, 2020.
   Google Scholar
• Almaaytah A, Mashaqbeh H, Haddad R. Current status of biosimilar regulations in the MENA region. Int J Res Pharm Sci. 2020;11(3):3443–3449. doi:10.26452/ijrps.v11i3.2484
   Google Scholar
• Farhat F, Othman A, Karak FE, Kattan J. Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region. Springerplus. 2016;5(1):2113. doi:10.1186/s40064-016-3779-8
   Google Scholar
• Almaaytah A, Elhajji FD. Comparative cost efficiency of the originator drug of infliximab and its biosimilar for the treatment of rheumatoid arthritis in the MENA region. Int J Pharm Investig. 2019;9(1):12–15. doi:10.5530/ijpi.2019.1.4
   Web of Science ®Google Scholar
• Watad A, Al-Saleh J, Lidar M, Amital H, Shoenfeld Y. Rheumatology in the Middle East in 2017: clinical challenges and research. Arthritis Res Ther. 2017;19(1):1. doi:10.1186/s13075-017-1359-0
   Web of Science ®Google Scholar
• Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–v84. doi:10.1093/annonc/mdv303
   PubMed Web of Science ®Google Scholar
• Dotan E, Aggarwal C, Smith MR. Impact of rituximab (Rituxan) on the treatment of B-cell non-Hodgkin’s lymphoma. Pharm Ther. 2010;35(3):148.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5. doi:10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• Ekström-Smedby K. Epidemiology and etiology of non-hodgkin lymphoma–a review. Acta Oncol (Madr). 2006;45(3):258–271. doi:10.1080/02841860500531682
   PubMed Web of Science ®Google Scholar
• Gulácsi L, Brodszky V, Baji P, Rencz F, Márta P. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–1144. doi:10.1007/s12325-017-0522-y
   PubMed Web of Science ®Google Scholar
• Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P, Shea BJ. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):1. doi:10.1371/journal.pone.0008933
   Web of Science ®Google Scholar
• Kasteng F, Wilking N, Jonsson B. Patient access to cancer drugs in nine € countries in the Middle East. Available from: http://www.comparatorreports.se/Middle%20East%20oncology%20drug%20uptake%20Final%20report%20Sept% 2015%202008.pdf. Accessed March 20, 2018.
   Google Scholar
• Kim J, Hong J, Kudrin A. Year budget impact analysis of biosimilar infliximab for the treatment of rheumatoid arthritis in UK, Italy, France and Germany. Arthritis Rheum. 2014;11(Suppl):S512.
   Google Scholar
• Jha A, Upton A, Dunlop WCN, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756. doi:10.1007/s12325-015-0233-1
   PubMed Web of Science ®Google Scholar
• Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316–1322. doi:10.1136/annrheumdis-2013-204627
   PubMed Web of Science ®Google Scholar
• Zanetti R, Tazi MA, Rosso S. New data tells us more about cancer incidence in North Africa. Eur J Cancer. 2010;46(3):462–466. doi:10.1016/j.ejca.2009.11.012
   Web of Science ®Google Scholar
• Ewa O, Gulácsi L. Budget-impact analyses. Pharmacoeconomics. 2009;27(10):807–827. doi:10.2165/11313770-000000000-00000
   Web of Science ®Google Scholar
• Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611–617. doi:10.1080/03007995.2019.1571296
   PubMed Web of Science ®Google Scholar
• Cohen H, Beydoun D, Chien D, et al. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33(12):2160–2172. doi:10.1007/s12325-016-0431-5
   PubMed Web of Science ®Google Scholar